2024-11-21 - Analysis Report
## UnitedHealth Group Inc (UNH) Stock Review

**1. Performance vs. S&P 500 (VOO):**

UnitedHealth Group Inc (UNH) is a diversified healthcare company offering a range of products and services.  The cumulative return of UNH is 206.92%, significantly outperforming the S&P 500 (VOO) with a cumulative return of 125.68%. The difference in returns is 81.24%, placing it in the 51.3rd percentile of its historical performance relative to the S&P 500.

**Alpha and Beta Analysis:**

The provided data shows consistently high CAGR (Compound Annual Growth Rate) for UNH over various periods, ranging from 57.0% to 129.6%.  Alpha values generally indicate outperformance compared to the market (Beta reflects market correlation; a beta of 1 indicates the stock moves with the market).  While alpha values fluctuate, they are mostly positive. Maximum drawdown (MDD) also varied significantly across different periods. Notably, the most recent period (2022-2024) shows lower CAGR and a negative alpha, indicating underperformance relative to the market during that specific timeframe.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 129.6% | 12.2% | 91.2% | 0.9 | 202.9 |
| 2016-2018  | 123.9% | 18.6% | 91.6% | 0.9 | 229.3 |
| 2017-2019  | 90.5% | 21.0% | 38.8% | 0.9 | 270.6 |
| 2018-2020  | 66.1% | 35.3% | 18.8% | 1.1 | 322.7 |
| 2019-2021  | 116.2% | 35.3% | 16.1% | 1.0 | 462.1 |
| 2020-2022  | 89.2% | 35.3% | 65.6% | 0.9 | 487.9 |
| 2021-2023  | 57.0% | 16.3% | 22.1% | 0.5 | 484.5 |
| 2022-2024  | 24.4% | 18.8% | -4.6% | 0.5 | 531.0 |


**2. Recent Price Movement:**

* Closing Price: 600.5 (Last Market: 600.83)
* 5-Day Moving Average: 590.51
* 20-Day Moving Average: 584.44
* 60-Day Moving Average: 584.12

The price is currently above all three moving averages, suggesting a short-term uptrend.  The relatively small difference between the closing price and the last market price indicates a stable market.


**3. Technical Indicators and Expected Return:**

* RSI: 61.84 (Slightly above neutral; not overbought)
* PPO: 0.0 (Neutral; no strong momentum)
* 20-Day Relative Strength Change: 8.15 (+), indicating a short-term upward trend.
* Expected Return (2+ years): 20.95% (Significant outperformance compared to the S&P 500 over the long term).  This is a projected excess return and not guaranteed.  The last market price of 600.83 doesn't reflect a sharp increase or decrease.

**4. Recent Financial Performance:**

The provided earnings data shows fluctuating EPS and revenue.  Note the negative EPS in Q2 2024.  A more complete picture requires comparing these figures against analyst expectations and industry benchmarks. Further analysis is needed to understand the underlying causes of these fluctuations.


| Date       | EPS     | Revenue         |
|------------|---------|-----------------|
| 2024-11-04 | 6.56    | 100.82 B$       |
| 2024-08-09 | 4.58    | 98.86 B$        |
| 2024-05-09 | -1.53   | 99.80 B$        |
| 2023-11-06 | 6.31    | 92.36 B$        |
| 2024-11-04 | 6.31    | 92.36 B$        | *(Duplicate entry?)*


**5. (Missing from original prompt)  Fundamental Analysis:**  The information requested in #5 is not provided in the original prompt.  Analysis would include a detailed review of financial statements (balance sheet, income statement, cash flow statement) and ratios (e.g., debt-to-equity, return on assets, etc.).

**6. Quarterly Financial Data Analysis:**

* **Revenue and Profitability:** Revenue is relatively stable, with profit margins fluctuating between 21% and 24.5%.  The recent quarter shows a slight decrease in profit margin compared to the previous quarters.
* **Capital and Profitability:** Equity and ROE (Return on Equity) show variability, with some quarters exhibiting negative ROE. This requires further investigation to understand the underlying causes, which could include accounting adjustments or specific business events.

**7. News and Recent Issues:**

*(This section requires real-time information from sources like Shacknews, FINBOLD, etc.  I cannot access real-time information.)*  To complete this section, I need to search recent news articles on UNH.  Look for earnings announcements, analyst ratings changes, and any significant company news.  This would include details on recent market outlook, analyst opinions, and performance highlights.

**8. Overall Analysis:**

UNH has demonstrated strong historical outperformance compared to the S&P 500.  However, recent performance (2022-2024) has been weaker, and some financial metrics require further scrutiny.  The company shows consistent revenue, but profit margins and ROE fluctuate, indicating potential risks and needing further investigation of financial statements for clarification. Technical indicators currently suggest a short-term upward trend, and the long-term expected return is positive.  A thorough analysis requires reviewing the latest news, analyst reports, and a comprehensive review of financial statements to understand the underlying drivers of the recent fluctuations and the potential for future growth.

**9.  English Report Summary:**

This report analyzes UnitedHealth Group Inc. (UNH) stock performance, comparing it to the S&P 500.  Historical data shows significant outperformance, though recent results have been less impressive. While revenue remains stable, profit margins and ROE display volatility.  Technical indicators suggest a short-term upward trend, and a long-term outlook suggests potential outperformance, but further investigation is needed to assess underlying risks and opportunities.  Analysis of recent financial statements, news articles, and analyst reports is crucial to arrive at a fully informed investment decision.  The inclusion of current market news and analyst opinions from sources like Shacknews and FINBOLD are crucial for completeness.  Significant points like the negative EPS in Q2 2024 and variability in ROE require further in-depth research.
